// App-Quantinova.ai

: Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells

Researchers

Presenter

  • Andrew Higham

Principal Investigators

  • Pradeep Karur

  • Natalie Jackson

  • Danen Cunoosamy

  • Paul Jansson

  • Dave Singh

Medical Centers

  • University of Manchester, Manchester, United Kingdom

  • Medicines Evaluation Unit, Manchester, United Kingdom.

  • AstraZeneca, Gothenburg, Sweden

Locations

  • United Kingdom

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • Mitogen-activated protein kinase

  • p38 Mitogen-activated protein kinases

  • Peripheral blood mononuclear cell

Drug/Treatment

  • Budesonide

  • AZD-7624

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved